Femoston Conti Dosage/Direction for Use

1 tab/day. Femoston Conti should be taken continuously without a break between packs. It can be taken with or without food.
Starting Femoston Conti: Femoston Conti should be used only in postmenopausal women >12 months after menopause. It is intended to prevent stimulation of the endometrium in postmenopausal women, usually resulting in amenorrhea. Before initiating treatment, pregnancy must be excluded.
Prevention of Osteoporosis: A number of risk factors may contribute to postmenopausal osteoporosis including early menopause, family history of osteoporosis; recent prolonged use of corticosteroids; a small frame; a thin frame; cigarette smoking. If several of these risk factors are present in a patient, consideration should be given to HRT.
For a maximum prophylactic benefit, treatment with HRT should commence as soon as possible after the menopause.
Protection appears to be effective for as long as treatment continues, however, data on estrogen therapy >10 years are limited. A careful reappraisal of the risk/benefit ratio should be undertaken before treating for longer than 5-10 years. For long-term use, see also Precautions.
Changing from other HRT: Patients changing from other HRT preparations to Femoston Conti should do so at the end of the estrogen plus progestogen phase without a tab-free interval.
Femoston Conti should be used only in postmenopausal women >12 months after menopause. If the menopausal status is not known (eg, because of previous use of sequential HRT or oral combination contraceptives), the endogenous estrogen may still be high. This could result in unpredictable bleeding patterns, especially in the 1st few cycles.